ClinicalTrials.gg
RecruitingNCT07120997Prune-UPUpdated Feb 4, 2026

Prunes Preventing Bone Loss in Perimenopause

An interventional study of Prunes and Calcium supplement in Perimenopausal Bone Loss, sponsored by Penn State University. Recruiting at 1 site in United States. Open to female participants aged 44 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Penn State University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
44 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Osteoporosis, Postmenopausal with a site in United States — 4 open to participants now, 11 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · United States.

Planned enrollment
56th of 95
124 · median 201
Started
2025
with 1 other
No phase
16 of 106
2 open now
Primary completion
2029-09
later than 10 of 10 live
Registered
105th of 106
by date

Among the 106 studies in Osteoporosis, Postmenopausal with a site in United States, this one is the 56th largest by planned enrollment of the 95 interventional ones that give a count, is one of 2 that started in 2025, is one of 16 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 105th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

4 of the 106 studies in Osteoporosis, Postmenopausal with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 44 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Osteoporosis, Postmenopausal with a site in United States, or all of them as a file.
02

Study summary

Dietary interventions of prune consumption during the transmenopausal period are innovative methods to prevent bone loss. Modern medicine does not intervene to prevent or attenuate this highly vulnerable period of bone loss which, if successfully attenuated, can potentially prevent/delay osteoporosis in women. The transmenopausal period represents an opportunistic window for the study because bone loss is at its greatest at this time, with females losing as much as 6-7% of bone. If this project is successful at attenuating bone loss, it can immediately be disseminated to the public to promote prune consumption to slow down and attenuate perimenopausal bone loss. As such, this project could improve the long-term bone health of females and avoid or delay osteoporosis and improve quality of life. The long-term goal of this study is to test the novel hypothesis that prune consumption for 18 months during the 3-year transmenopausal period prevents the dramatic rate of bone loss in perimenopausal females during a window of heightened physiological vulnerability. At Penn State University, the study will compare the effects of 18 months of daily dietary consumption of 50 g of prunes (5-6) versus a no-prune control group on bone outcomes (bone mineral density, bone geometry), mechanistic factors (bone and inflammatory markers, inflammatory response of ex vivo cultured peripheral blood mononuclear cells, monocytes), and gut microbiome.

Read the detailed description

Females spend at least one-third of their lifespan after menopause, therefore strategies that improve the long-term health of women and engage a prevention strategy to improve health are warranted and represent opportunities for high impact and high return on investment. After menopause, one in two females will suffer a fragility fracture in their lifetime, and the mortality rate after a hip fracture is as high as 25%. Moreover, since osteoporosis-related treatment costs more than $100 billion worldwide, strategies that focus on the prevention of osteoporosis-related fragility fractures are warranted. As such, the prevention of bone loss, osteoporosis, and its related fractures is much preferred over treatment of osteoporosis given the high costs, negative side effects, and poor compliance to pharmacological treatment regimens. Therefore, research addressing the optimization of the health of perimenopausal females to delay chronic disease is very much necessary and represents the overall objective of this project. Given the high mortality rate of hip fractures, this intervention may potentially save people's lives while reducing a significant healthcare burden.

The long-term goal of this project is to change the course of bone loss during a very specific and opportunistic intervention window, i.e., the transmenopausal window. This window of intervention is opportunistic because females lose more bone at the hip and spine than at any other time; that is, as much as 6% and 7% at the hip and spine, respectively. In fact, the amount of bone loss during this three-year transmenopausal window that initiates late perimenopause is greater than the amount of bone loss observed during the postmenopause window, when the latter is defined as 2 to 5 years after the final menstrual period. The STRAW+10 investigators defined the stages of menopause, including the transmenopause period, a stage in life that is associated with dramatic bone loss. As such, this project is novel, innovative, and can potentially delay the serious effects of osteoporotic bone loss and associated fractures, to which transmenopausal bone loss significantly contributes. When one considers that as of 2021, there were approximately 1.02 billion females over 50 years of age worldwide, with an estimated 1.2 billion females over the age of 50 by 2030, accounting for 26% of all females worldwide, the potential impact of this project is substantial. Indeed, this project may affect the long-term picture of bone health for millions of females by delaying or attenuating the acceleration of bone loss during the transmenopause period. Moreover, since osteoporosis affects millions of females worldwide, this project has the potential to offset the devasting long-term effects of accelerated bone loss during transmenopause that is associated with osteoporosis.

The overall objective of this research is to test whether prunes are effective in attenuating the rapid transmenopausal bone loss observed in late peri and early postmenopausal females. The investigators will study the effects of 18 months of prune consumption in females recruited during the late peri and early postmenopausal stage, allowing a high probability for data collection spanning the transmenopausal period of heightened bone loss, i.e., 12 months before the final menstrual period and the two years following the final menstrual period. The investigators will also examine the physiological mechanisms underlying the bone trophic effects of prune consumption to seek evidence on how prunes work. If successful, prunes will be demonstrated to be a powerful strategy to attenuate and delay the rapid decline in bone mineral density and decrements in microarchitecture that eventually lead to osteoporosis and heightened risk for fracture.

03

Conditions studied

  • Perimenopausal Bone Loss

Keywords

  • Female
  • Transmenopause
  • Perimenopause
  • Perimenopausal Bone Loss
  • Menopause
  • Human
  • Osteoporosis
  • Non-pharmacologic therapy
  • Prune intake
  • Dried Plum
04

Who can participate

Ages eligible
44 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 44 to 55 years
  • Not severely obese ( \<35 kg/m\^2)
  • Healthy (determined by a screening questionnaire, physical and medical history by a certified nurse practitioner, complete metabolic panel, and complete blood count)
  • Willing to include prunes in their daily diet
  • Not taking any natural dietary supplement containing phenolics, i.e.,\< 1 cup/day of blueberries or apples for at least 2 months prior to study entry
  • Non-smoking
  • Ambulatory
  • No menses for ≥60 days but not more than 18 months post final menstrual period
  • Only participants who have a determinable natural (not surgical) final menstrual period date are eligible

Exclusion criteria

Exclusion Criteria:

  • Subjects who regularly consume prunes, dried apples, prune juice, or heavy consumers of blueberries (1 cup or more/day)
  • History of vertebral fracture or fragility fracture of the wrist, humerus, hip or pelvis after age 45 yr)
  • Untreated hyper- or hypothyroidism
  • Current hyper- or hypoparathyroidism
  • Significantly impaired renal function
  • Current hypo- or hypercalcemia
  • History of spinal stenosis
  • History of heart attack, stroke, thromboembolism, kidney disease, malabsorption syndrome, or seizure disorders
  • Positive for , Hep-C or Hep-B surface antigen and
  • Use of the following agents affecting bone metabolism: intravenous bisphosphonates at any time; fluoride (for osteoporosis) within the past 24 months; denosumab at any time; bisphosphonates, parathyroid hormone or strontium within the past 12 months; calcitonin; selective estrogen receptor modulators within the past 12 months; systemic oral or transdermal estrogen within the past 3 months; systemic glucocorticosteroids (≥ 5 mg prednisone equivalent per day for more than 10 days); or tibolone within the past 3 months
  • Hormonal within the past three months
  • Subjects who will not consume study provided dietary items or who will not stop taking their own natural product supplements
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Calcium and Vitamin D - Control group

    Participants will take calcium and vitamin D supplements daily for a baseline period and for the duration of the intervention. Participants will be asked to refrain from consumption of prunes and fruits that have high phenolic content for the duration of the intervention (18 months).

    Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D Supplement

  • Experimental
    50g Prunes, Calcium, and Vitamin D - Intervention Group

    Participants will take calcium and vitamin D supplements daily for a baseline period and for the duration of the intervention. Additionally, participants will be provided with prunes and asked to consume 6 (50g) prunes per day for the duration of the intervention (18 months).

    Dietary Supplement: Prunes · Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D Supplement

Interventions

  • Dietary supplementPruneStudies of PrunePrune pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants randomized to the 50g prune group will consume 6 prunes per day for the duration of the 18-month intervention.

  • Dietary supplementCalcium supplement

    All participants will consume calcium supplements daily for a baseline period and for the duration of the 18-month intervention.

  • Dietary supplementVitamin DStudies of Vitamin DVitamin D pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All participants will consume Vitamin D supplements daily for a baseline period and for the duration of the 18-month intervention.

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in areal bone mineral density (via DXA) of the lumbar spine, total hip, and femoral neck

    Percent change in areal bone mineral density measured at baseline, month 9, and month 18 of the 18-week dietary intervention at the lumbar spine, total hip, and femoral neck.

    Time frame: Baseline, month 9, month 18

Secondary outcomes

  1. Changes from baseline in Spine Trabecular Bone Score (TBS) (via DXA)

    Changes in Spine Trabecular Bone Score (TBS) assessed at baseline, month 9, and month 18 of the 18-month dietary intervention from lumbar spine DXA scans. The measurements will provide additional information about the effects of the intervention on trabecular bone.

    Time frame: Baseline, month 9, and month 18

  2. Percent change from baseline in volumetric BMD of the tibia and radius (via pQCT)

    Percent change in volumetric BMD, cortical and trabecular compartments, measured during baseline, month 9, and month 18 of the 18-month dietary intervention at the tibia and radius. The combination of measurements will provide an overall picture of the 3-dimensional structure of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.

    Time frame: Baseline, month 9, and month 18

  3. Percent change from baseline in bone geometry measurements of the tibia and radius (via pQCT)

    Percent change in bone geometry estimates (total bone area, cortical and trabecular area, cortical thickness) measured during baseline, and month 9, and month 18 of the 18-month dietary intervention at the tibia and radius. The combination of measurements will provide an overall picture of the 3-dimensional structure of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.

    Time frame: Baseline, month 9, and month 18

  4. Percent change from baseline in bone strength index of the tibia and radius (via pQCT)

    Percent change in bone strength index (BSI) measured during baseline, and month 9, and month 18 of the 18-month dietary intervention at the tibia and radius. The measurement will provide an overall picture of bone strength and of the 3-dimensional structure of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.

    Time frame: Baseline, month 9, and month 18

  5. Percent change from baseline in stress strain index of the tibia and radius (via pQCT)

    Percent change in stress strain index (SSI), a bone strength measurement, measured during baseline, month 9, and month 18 of the 18-month dietary intervention at the tibia and radius. The measurements will provide an overall estimate of bone strength of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.

    Time frame: Baseline, Month 9, Month 18

  6. Percent change from baseline in polar moment of inertia measurements of the tibia and radius (via pQCT)

    Percent change in polar moment of inertia (section modulus) measured during baseline, and month 9, and month 18 of the 18-month dietary intervention at the tibia and radius. The measurement will provide an overall picture of the 3-dimensional structure and bone strength of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.

    Time frame: Baseline, Month 9, Month 18

  7. Change from baseline in C-terminal telopeptide of type I collagen (CTx)

    Change in serially-sampled fasting serum concentrations of C-terminal telopeptide of type I collagen (CTx), a marker of bone resorption, at baseline, month 9, and month 18 of the 18-month dietary intervention. Changes in bone resorption markers will assist in understanding the underlying mechanisms behind changes in the rates of bone resorption.

    Time frame: Baseline, month 9, and month 18

  8. Change from baseline in Tartrate-resistant acid phosphatase (Trap 5b)

    Change in serially-sampled fasting serum concentrations of Tartrate-resistant acid phosphatase (Trap 5b), a marker of bone resorption, at baseline, month 9, and month 18 of the 18-month dietary intervention. Changes in bone resorption markers will assist in understanding the underlying mechanisms behind changes in the rates of bone resorption.

    Time frame: Baseline, month 9, and month 18

  9. Change from baseline in expression of inflammatory markers

    Change in lipopolysaccharide(LPS)-stimulated peripheral blood mononuclear cell (PBMC) gene expression of inflammatory markers (interleukin-1β, interleukin-6, and tumor necrosis factor-α) at baseline, month 9, and month 18 of the dietary intervention. Additionally, the relationship between the changes in gene expression of inflammation markers and bone outcomes will be explored. The combined changes of the gene expression of inflammatory markers will provide a comprehensive picture of the inflammatory environment of the participants before, during and following the dietary intervention. This comprehensive picture will assist in understanding the mechanisms by which the inflammatory environment contributes to bone loss in transmenopause and how the dietary intervention impacts those factors.

    Time frame: Baseline, month 9, and month 18

  10. Change from baseline in gut permeability

    Change in serially-sampled fasting serum concentrations of zonulin, a gut permeability marker, at baseline, month 9, and month 18 of the 18-month dietary intervention. Changes in zonulin will assist in understanding the underlying mechanisms of changes in the gut and bone metabolism.

    Time frame: Baseline, month 9, and month 18

  11. Change from baseline in gut microbiome

    Serially-sampled stool samples for assessment of changes in the Beta diversity of gut microbiome at baseline, month 9, and month 18 of the 18-month dietary intervention. Additionally, the relationship between the changes in the gut microbiome and bone outcomes will be explored.

    Time frame: Baseline, month 9, and month 18

07

Study locations

1 of 1 sites recruiting
  • Women's Health and Exercise Laboratory, The Pennsylvania State University
    University Park, Pennsylvania 16802, United States
    Recruiting
    • Mary Jane De Souza, PhD · Contactmjd34@psu.edu · 814-863-0045
    • Nancy I. Williams, ScD · Contactniw1@psu.edu · 814-865-1346
    • Mary Jane De Souza, PhD · Principal investigator
    • Nancy I. Williams, ScD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2029, 45 months after the start.

Of 48 non-industry interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 45 months is above that.

Counting every sponsor, half of 51 studies reached it within 17 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 13, 2025
StartActual
Dec 11, 2025
Primary completionEst.
Sep 2029
CompletionEst.
Dec 2029
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07120997
Collaborators
University of Georgia, California Dried Plum Board, United States Department of Agriculture (USDA)
Responsible party
Mary Jane DeSouza (Distinguished Professor of Kinesiology and Physiology, Penn State University) — Principal investigator
First posted
Aug 13, 2025
Start date
Dec 11, 2025
Primary completion
Sep 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Feb 4, 2026

Study contacts

Mary Jane De Souza, PhD
Contact
mjd34@psu.edu
814-863-0045
Nancy I. Williams, ScD
Contact
niw1@psu.edu
814-865-1346

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prune

Start the discussion